Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03990896
Title Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Massachusetts General Hospital
Indications

triple-receptor negative breast cancer

Her2-receptor negative breast cancer

Therapies

Talazoparib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.